WHO Declares Lymphatic Mapping to Be the Standard of Care for Melanoma

Publication
Article
OncologyONCOLOGY Vol 13 No 3
Volume 13
Issue 3

Dr. Natale Cascinelli, president of the World Health Organization (WHO) Melanoma Program, declared intraoperative lymphatic mapping to be the standard of care for melanoma. He made this statement during his presentation of the abstract, “An Overview on Sentinel Lymph Node Dissection” at the 9th International Congress on Anti-Cancer Treatments in Paris.

Dr. Natale Cascinelli, president of the World Health Organization (WHO) Melanoma Program, declared intraoperative lymphatic mapping to be the standard of care for melanoma. He made this statement during his presentation of the abstract, “An Overview on Sentinel Lymph Node Dissection” at the 9th International Congress on Anti-Cancer Treatments in Paris.

In his abstract, Dr. Cascinelli stated, “..sentinel node biopsy represents the key to select patients harboring clinically inapparent metastatic nodes and the concept of selective dissection is introduced as the clue to overcome unuseful elective nodal dissections. Sentinel node biopsy is a reliable and safe procedure for accurate staging of clinical stage I melanoma patients and for adequate selection of patients to submit to nodal dissections and adjuvant treatments. The adoption of preoperative lymphoscintigraphy and intraoperative probe drastically increases the chance for SN identification. The status of SN represents at multivariate analysis a mostly important prognostic factor for overall and disease-free survival. Sentinel node biopsy currently represents the standard of care in the management of stage I melanoma patients and the starting point for future policies on surgery and adjuvant treatment strategies.”

More Appropriate Staging

Physicians use intraoperative lymphatic mapping to trace the lymphatic patterns in a patient. Evaluation of the potential tumor drainage and spread is intended for the purpose of more appropriately staging patients. Lymphatic mapping begins with a patient being injected with a commercially available radioactive tracing agent, eg, filtered sulfur colloid labeled with techne-

tium-9mm, at the tumor site. The agent is intended to follow the same lymphatic flow as the tumor would if it had metastasized or spread. The surgeon may then track the agent’s path with the probe, thus following the potential avenues of tumor spread and identifying the sentinel lymph nodes to be tested for cancer.

Articles in this issue

WHO Declares Lymphatic Mapping to Be the Standard of Care for Melanoma
Rituximab: Phase II Retreatment Study in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma
Response Criteria for NHL: Importance of “Normal” Lymph Node Size and Correlations With Response
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
A Randomized Trial of Fludarabine, Mitoxantrone (FM) Versus Doxorubicin, Cyclophosphamide, Vindesine, Prednisone (CHEP) as First Line Treatment in Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma: A Multicenter Study by GOELAMS Group
Navelbine Increased Elderly Lung Cancer Patients’ Survival
Fludarabine Versus Conventional CVP Chemotherapy in Newly C Diagnosed Patients With Stages III and IV Low-Grade Malignant Non-Hodgkin’s Lymphoma: Preliminary Results From a Prospective, Randomized Phase III Clinical Trial in 381 Patients
Multicenter, Phase III Study of Iodine-131 Tositumomab (Anti-B1 Antibody) for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma
T-Cell–Depleted Allogeneic Bone Marrow Transplant From HLA-Matched Sibling Donors for Non-Hodgkin’s Lymphoma
Consensus Statement on Prevention and Early Diagnosis of Lung Cancer
In Vivo Purging and Adjuvant Immunotherapy With Rituximab During PBSC Transplant For NHL
Fludarabine and Cyclophosphamide: A Highly Active and Well-Tolerated Regimen for Patients With Previously Untreated Indolent Lymphomas
Campath-1H Monoclonal Antibody in Therapy for Advanced Low-Grade Non-Hodgkin’s Lymphomas: A Phase II Study
AIDS Drugs Effective Against Most Common HIV Strain
Rituximab Therapy in Previously Treated Waldenström’s Macroglobulinemia: Preliminary Evidence of Activity
Recent Videos
Experts on myeloma
Related Content